AORT (54) DRTS (33) IRMD (68) SGP (41) ⌘ Pro Terminal →

PROCEPT BioRobotics Corporation (PRCT) — RQD Stock Rating Cockpit

$20.30 +0.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.28

PROCEPT BioRobotics Corporation (PRCT) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $1.16B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $20.28 (-0.10%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRCT)Realized 20D OHLCV Swing Band: ±11.4%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY PRCT SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (29% of score)

Altman Z-Score 3.98 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (25% of score)

FRED Regime × Technicals: 17% of 52W Range • RSI-14 at 50.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$18.40-4.5% Next Q

Q2 (-2Q)

Grade D$17.57+13.6% Next Q

Q3 (-1Q)

Grade D$19.96+1.7% Next Q

Current

Grade D$20.30-5.6% Hist 90D α

Trajectory: D (40) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRCT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRCT currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.40) and Max Pain ($21.32) forces dealer call-delta covering toward $40.02.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

50.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.98>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE17% OF RANGE

L: $17$20.30H: $38

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on PRCT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 63.7% gross margin and -5.02% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 3.98 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (45)

15/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like PRCT

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRCT)

✓Walkthrough of PRCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -15.56%📐 HORIZONTAL RANGE

2026-10-30O $20.33H $20.37L $18.90C $20.30VOL 856.5K

RES: $21.67SUP: $16.77SMA50: $19.40SMA200: $23.32

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRCT Butterfly Map → + Track PRCT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +37.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRCT)

Health Care Rank #379 of 1016 ⚔️ AORT vs PRCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRCT vs. AORT, DRTS, IRMD, SGP)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, PROCEPT BioRobotics Corporation (PRCT) ranks #379 by composite RQD confidence (48/100, grade D) and #341 by equity capitalization ($1.16B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with PRCT at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRCT ACTIVE PROCEPT BioRobotics Corporation	D	48/100	—	63.7%	-35.0%	+0.50%	$1.16B	Benchmark Subject
AORT Artivion Inc.	D+	54/100	117.0x	64.4%	4.5%	+2.27%	$1.14B	/aort-vs-prct →
DRTS Alpha Tau Medical Ltd.	E	33/100	—	—	-35.0%	-0.90%	$1.22B	/drts-vs-prct →
IRMD iRadimed Corporation	C+	68/100	48.8x	76.7%	37.7%	+2.16%	$1.10B	/irmd-vs-prct →
SGP SpyGlass Pharma Inc.	D-	41/100	—	—	-35.0%	-1.06%	$1.09B	/sgp-vs-prct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001588978

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PROCEPT BioRobotics Corporation (PRCT) reported GAAP revenue of $308.1M (+37.2% vs. FY2024 revenue of $224.5M , and +126.2% cumulative change since FY2023) , GAAP net income of -$95.6K, operating cash flow of -$49.0M, and free cash flow of -$58.3M (+43.7% YoY). On the balance sheet, PRCT closed FY2025 with $508.1M in total assets against $51.6M in total debt (Altman Z-Score: 3.98, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$308.1M	-$95.6K	-$49.0M	-$58.3M	$508.1M	$51.6M
FY2024 (FY)	2024-12-31	$224.5M	-$91.4K	-$99.2M	-$103.6M	$534.0M	$51.5M
FY2023 (FY)	2023-12-31	$136.2M	-$105.9K	-$108.0M	-$108.0M	—	—

3. PRCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $20.30 (+0.50% 1D, market cap $1.16B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PRCT ranks #379 in composite RQD confidence.

How does PRCT compare to AORT and DRTS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PRCT carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 63.7%, and ROIC of -35.0%. By comparison, AORT (Artivion Inc.) holds a D+ grade (54/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B) and DRTS (Alpha Tau Medical Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRCT?

Per PRCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001588978), PROCEPT BioRobotics Corporation generated $308.1M in revenue (+37.2% YoY), -$95.6K in net income, and -$58.3M in free cash flow against $508.1M in total assets and $51.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRCT trading relative to its 50-day, 200-day, and 52-week technical levels?

PRCT last traded at $20.30 (+0.50% on volume of 704,592 shares), positioning the stock +4.64% above its 50-day simple moving average ($19.40) and -12.95% below its 200-day simple moving average ($23.32). Across its 52-week range of $16.67 to $38.11, PRCT sits at the 16.9% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.4% ($17.99 to $22.61).

PRCT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PRCT stock right now?

PROCEPT BioRobotics Corporation (PRCT) currently earns a Roarable Rating of D (Sell — SELL) with 48/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is PRCT's 12-month price target and RQD AI Jury consensus?

PRCT's 12-month base price target is $19.39 (range $15.12 to $40.02), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PRCT RQD Cockpit PRCT 12M Forecast PRCT Earnings & Move PRCT Dividends & DRIP PRCT Insiders & 13F PRCT Whale Options PRCT Profit Sankey PRCT News & Why